GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

CARVYKTI net trade sales rose 36% in Q3 2026 to approximately $710 million compared to Q3 2025.
Five-year CARTITUDE-2 Cohort A data showed 50% of patients remained alive and progression-free without further treatment after a single infusion.
Updated NCCN Guidelines recommend referring all multiple myeloma patients to a T-cell therapy capable center at first relapse.
Legend Biotech received FDA IND clearance for LB2501, a dual-targeting in vivo CAR-T therapy for B-cell malignancies.
Ingrid Zhang was appointed Chief Executive Officer effective September 15, 2026.
Cash, cash equivalents, and time deposits totaled approximately $853 million as of September 30, 2026.
Collaboration revenue reached $353.2 million in Q3 2026, driven by increased CARVYKTI sales under the Janssen agreement.
Operating income turned positive at $46.8 million in Q3 2026, a significant improvement from a $43.3 million loss in the prior year period.
Net income for the three months ended September 30, 2026, was $51.7 million, reversing a $39.6 million net loss in the same period of 2025.
CARVYKTI is now available at 373 treatment sites across 20 global markets.
Research and development expenses decreased to $95.3 million in Q3 2026 due to reduced cilta-cel clinical program spending.
Administrative expenses fell to $14.8 million in Q3 2026, primarily due to lower share-based compensation expenses.